#### Edgar Filing: ALLERGAN INC - Form 4

ALLERGAN Form 4 May 01, 2014												
FORM	Л									OMB A	PPROVA	۱L
	UNITED	STATES		RITIES A				E COMMISSIO	ON	OMB Number:	3235-	0287
Check this if no longe subject to Section 16 Form 4 or Form 5 obligations may contir <i>See</i> Instruct 1(b).	Filed pur Section 17(	rsuant to S (a) of the I	OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES o Section 16(a) of the Securities Exchange Act of 1934, e Public Utility Holding Company Act of 1935 or Section h) of the Investment Company Act of 1940							Expires: Estimated burden hou response	average urs per	ry 31, 2005 0.5
(Print or Type Re	esponses)											
1. Name and Address of Reporting Person <u>*</u> Dunsire Deborah			2. Issuer Name <b>and</b> Ticker or Trading Symbol					5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (	Middle)	ALLERGAN INC [AGN] 3. Date of Earliest Transaction				(C	heck	eck all applicable)			
2525 DUPONT DRIVE			(Month/Day/Year) 04/29/2014				X_ Director10% Owner Officer (give titleOther (specify below) below)					
IRVINE, CA	4. If Amendment, Date Original Filed(Month/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting Person</li> </ul>							
(City)	(State)	(Zip)	Tab	ole I - Non-	Derivat	tive S	ecurities A	Acquired, Dispose	d of,	or Beneficia	lly Owned	d
	. Transaction Date Month/Day/Year)	2A. Deem Execution any (Month/Da	ed Date, if	3. Transactic Code (Instr. 8) Code V	4. Sec onAcqui Dispo (Instr.	curitie ired (A osed of . 3, 4 a (	s A) or f (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Fo (D (I)	Ownership orm: Direct O) or Indirect	7. Nature Indirect	e of 1l
Reminder: Repo	rt on a separate line	e for each cl	ass of sec	urities bene	ficially	owne	d directly	or indirectly.				
					inf rec dis	iorma quire	ation con d to resp s a curre	spond to the col tained in this for ond unless the ently valid OMB o	rm a form	ire not	SEC 1474 (9-02)	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8. Pric
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onof Derivative	Expiration Date	Underlying Securities	Deriva
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	Securi
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired			(Instr.

	Derivative Security				<ul><li>(A) or</li><li>Disposed of</li><li>(D)</li><li>(Instr. 3, 4, and 5)</li></ul>						
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Phantom Stock Units	(1)	04/29/2014	А		15.09 (2)		(3)	(3)	Common Stock	15.09	\$ 16

#### **Reporting Owners**

Reporting Owner Name / Address	Relationships								
	Director	10% Owner	Officer	Other					
Dunsire Deborah 2525 DUPONT DRIVE IRVINE, CA 92612	Х								

### Signatures

/s/ Matthew J. Maletta, Attorney-in-Fact for Deborah Dunsire

\*\*Signature of Reporting Person

05/01/2014 Date

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Converts to common stock on a 1-for-1 basis.

(2) Phantom stock units acquired under the Allergan, Inc. Deferred Directors' Fee Program.

(3) Phantom stock units are to be settled 100% in common stock upon the Reporting Person's retirement as an Allergan, Inc. director.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.